JAK2 and acquired polycythemia vera: In particular, a somatic mutation in the JAK2 protein, V617F, was identified in myeloproliferative neoplasms, including 95% of patients with polycythemia vera and ~50% of patients with essential thrombocythemia and primary myelofibrosis (20).